RESOURCES
-
-
-
March 18, 2026
Advancing Antifungal Drug Development with Preclinical Fungal Infection Platform
GemPharmatech's BSL-2 biosafety laboratory maintains a comprehensive library of clinically relevant fungal strains, including Candida albicans, Candida auris, Aspergillus fumigatus, and Aspergillus flavus. Our team has established validated systems for fungal culture, murine infection modeling, and multi-endpoint readout detection. Our established models — spanning fungal sepsis, invasive pulmonary aspergillosis, and cutaneous fungal infection — have been successfully deployed to support efficacy evaluation of multiple antifungal compounds, delivering robust and reliable data.
-
-
-
-
March 09, 2026
Advancing Heart Failure Research: A Comprehensive Guide to Preclinical HFrEF and HFpEF Models
Heart failure (HF) remains a global healthcare crisis, with two distinct phenotypes—Heart Failure with Reduced Ejection Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF)—posing unique challenges for drug development and translational research. To accelerate breakthroughs, robust preclinical models that recapitulate human disease pathophysiology are essential. Below, we break down a curated panel of validated HFrEF and HFpEF models, designed to empower researchers in selecting the right tool for their studies.
-
-
-
-
March 05, 2026
From Weight Loss to Fat Loss with Muscle Preservation: The Evolving Paradigm in Anti-Obesity Drug Evaluation
As an innovator in laboratory animal models, GemPharmatech provides high-quality genetically engineered rodent models and comprehensive technical services to academic institutions and pharmaceutical companies worldwide. Our portfolio includes diet-induced obesity (DIO) models and related metabolic disease models in both mice and rats, enabling robust simulation of human metabolic disorders. Through advanced gene-editing technologies, we provide drug target humanized models to facilitate mechanistic exploration of anti-obesity therapeutics. In addition, we offer integrated services including body composition analysis and energy metabolism assessment, enabling precise evaluation of drug effects across adipose tissue, skeletal muscle, and multiple metabolic organs. From model selection to data interpretation, we provide end-to-end solutions to accelerate translational research.
-
-
-
-
February 09, 2026
GemPharmatech Mouse Models Support Discovery in Cell Publication: Revealing a Novel Treg-Mediated Mechanism of Immunotherapy Resistance
GemPharmatech’s models were used in a publication accepted by the prestigious journal Cell. The study reveals a fundamental new mechanism of tumor immune evasion. It demonstrates that tumor-produced ammonia is metabolically utilized by regulatory T cells (Tregs), enhancing their immunosuppressive capacity and driving resistance to treatment. In cancer immunotherapy, understanding how metabolic byproducts in the tumor microenvironment (TME) influence immune cells is a central focus. Read the blog to learn how GemPharmatech's mouse models were instrumental in this research.
-
-
-
-
January 29, 2026
Advancing PVR Research: A Novel Transgenic Mouse Model with Spontaneous Disease Phenotype
Proliferative Vitreoretinopathy (PVR) is the formation of scar tissue in the eye after complication of retinal detachment or eye injury. At present, the therapeutic approaches for PVR are limited, with surgery still serving as the core treatment. Based on years of experience in transgenic mouse research and development, GemPharmatech has developed a novel B6-Rho-hVEGFA-Tg transgenic mouse model. By 4 weeks of age, it exhibits typical ocular pathological features, including abnormal retinal neovascularization, retinal structural detachment, and formation of proliferative membranes, thereby serving as a novel tool for research on proliferative vitreoretinopathy (PVR) and other related neovascular ophthalmic diseases.
-
-
-
-
December 15, 2025
Fabry Disease Mouse Models for Preclinical Efficacy Evaluation
Fabry disease (FD) is a rare, progressive, X-linked inherited disorder caused by deficient or absent lysosomal α-galactosidase A (α-GAL) activity, leading to impaired glycosphingolipid metabolism. To accelerate FD research and help researchers better understand disease mechanisms and develop new treatments, GemPharmatech has developed two GLA gene knockout mouse models: Gla-KO and NCG-Gla-KO.
-
-
-
-
December 11, 2025
A Novel Mouse Model of Atherosclerosis for Testing PCSK9-Targeted Therapeutics
Atherosclerosis is pathologically characterized by the subendothelial buildup of lipids, extracellular matrix, and cholesterol-laden macrophages, which collectively form atherosclerotic plaques. The liver-secreted protein PCSK9 promotes the lysosomal degradation of the hepatic LDL receptor (LDLR) through direct binding. This process impairs LDL clearance and elevates circulating LDL-C (low-density lipoprotein cholesterol), a central driver in the pathogenesis of atherosclerosis. Consequently, this pathophysiological pathway establishes PCSK9 as a validated therapeutic target for treating atherosclerosis.
-
-
-
-
November 17, 2025
Immune-Related Cytotoxicity Evaluation Platform for In Vitro Pharmacodynamics
Antibody drugs exert antitumor effects by regulating immune function. Their core mechanism lies in specific binding to antigens on the surface of tumor cells, enabling precise killing of tumor cells in synergy with immune cells. In this process, the Fc region of antibodies mainly relies on three key effector functions—ADCC, ADCP, and CDC—which together form the antibody-mediated antitumor immune network. This article introduces GemPharmatech’s in vitro immune-related cytotoxicity evaluation platform and illustrates its capabilities through a series of case studies that show how each mechanism is measured, compared, and applied in drug development.
-
-
-
-
November 10, 2025
Preclinical Mouse Models for Reliable ALS Therapeutic Insights
Amyotrophic Lateral Sclerosis (ALS), often known as Lou Gehrig's disease, is the third most prevalent neurodegenerative disorder worldwide. It relentlessly targets motor neurons in the brain and spinal cord, leading to progressive muscle weakness, paralysis, and ultimately, respiratory failure. For the hundreds of thousands of patients and families it affects globally, every new research breakthrough brings new hope for finding a cure.
-